# Supplemental -Table of Content

A- Methods

DNA extraction and 16S sequencing; Estimation of alpha and beta diversity; Pathway analyses; Network analyses; Assays of circulating biomarkers. References

## B- <u>Tables</u>

Table 1: Comparison of the NYC and BCN cohorts at pre-surgery.

Table 2: Comparison of the effect of surgery at 1 year in the NYC and BCN cohorts. Table 3: Comparison of the two surgery groups (SG n=7 and RYGB n=5) in the BCN cohort.

Table 4: Spearman correlations between individual circulating bile acids and stool bacteria.

Table 5: Bile acids definitions

## C- Figures

Figure 1: Magnitude of change (express as % increase or decrease) of clinical characteristics, circulating biomarkers of metabolism, of inflammation and of microbial metabolism.

Figure 2: Pathway Analysis

Figure 3: Correlations Analyses

Figure 4: Network Analyses

## <u>Methods</u>

#### Microbiome analyses

## DNA extraction and 16S sequencing

DNA was extracted from fecal samples using the PowerLyzer PowerSoil DNA isolation kit (MoBio, Carlsbad CA). DNA quality and quantity were measured with the Nanodrop 1000 (Thermo Fisher Scientific, Wilmington DE). For each sample, the V4 region of bacterial 16S rRNA genes was amplified in triplicate reactions using the universal bacterial primer set 515F/806R, which amplifies bacterial and archaeal 16S rRNA genes<sup>(1)</sup>. PCR reactions contained 12 µl molecular biology grade water (Corning Cellgro, Atlanta GA), 10 µl 5 Prime Hot Master Mix (5 Primer, Inc., Gaithersburg MD), 1.0 µl each of the forward and reverse primers (each at 5 µM final concentration), and 1 µl genomic DNA. Reactions were held at 94°C for 3 min to denature the DNA, run for 35 cycles of amplification at 94°C for 45s, 50°C for 60s, and then 72°C for 90s, and completed with a final extension step of 10 min at 72°C. Amplicons from each sample were quantified using the PicoGreen dsDNA Assay Kit (Life Technologies, Eugene OR). Equal amounts of DNA from each sample were pooled, followed by PCR purification (Qiagen, Hilden, Germany). DNA concentrations in these sub-pools were quantified with the Qubit high sensitivity dsDNA Assay (Life Technologies), and combined at equal concentrations.

DNA sequencing was performed using the NYULMC Genome Technology Center Illumina MiSeq platform. The sequencing reactions generated 151-base-pair forward and reverse reads and a 12-base-pair barcode read.16S rRNA sequencing reads were demultiplexed and quality filtered using QIIME version 1.9.1 with default settings as described<sup>(2)</sup>. Filtered reads were clustered into operational taxonomic units (OTUs) using a closed-reference OTU picking algorithm<sup>(3)</sup> with 97% similarity threshold against the GreenGenes database V13.8<sup>(4)</sup>.

#### Alpha and beta diversity

Alpha diversity was estimated using rarefied OTU tables at 5,000 sequences per sample, using Faith's phylogenetic diversity metric<sup>(5)</sup>. Beta diversity was estimated using unweighted UniFrac<sup>(6)</sup> on the rarefied OTU tables, and principal coordinate analyses (PCoA) was performed using the resulting UniFrac distance matrices. Significance of alpha diversity differences over time was estimated using repeated measures ANOVA on the diversity values obtained at 5,000 sequences/sample. Differences were considered significant, when p < 0.05, unless otherwise indicated.

Random forests were constructed using OTUs in each sample as features of the model and as implemented in QIIME through the supervised\_learning.py command, with 500 trees and leave-one-out error estimation<sup>(7)</sup>. Accuracy of the classifier was estimated by dividing the observed error by the percentage of subjects in the majority class, with ratios below 2 indicating poor classification accuracy<sup>(7)</sup>. The relative importance of each OTU in the model (i.e. its predictive power) was assessed by estimating the expected mean decrease in accuracy when the OTU is excluded from the model, with higher decreases in accuracy corresponding to larger predictive power.

Analysis of enrichment/depletion of specific bacterial taxa in subgroups of patients (e.g. pre- versus post-surgery) was performed using LEfSe<sup>(8)</sup>. Significant taxa with linear discriminant log-scores larger than 2.0 were reported. A random forest classifier was used to test differences between subjects from the NYC and the BCN cohorts based on their microbiome composition<sup>(7)</sup>.

### Pathway Analyses

Bacterial functions were inferred from the 16S rRNA data using PICRUSt<sup>(9)</sup>. The OTU table was normalized by the 16S rRNA gene copy number of each OTU, and functions were predicted from the normalized table and expressed as counts of KEGG orthologs (KOs) for each sample, with each KO being annotated to a KEGG pathway. Differential analysis of pathways was performed using STAMP v2 with default parameters<sup>(10)</sup>, and significance of differences in pathway enrichment/depletion was estimated using ANOVA and the Tukey-Kramer post-hoc test.

## Network Analyses

Co-occurrence network analyses were performed by filtering out singletons (OTUs with a single count) and summarizing the remaining OTUs at the genus level. Co-occurrences between genera were then estimated using SparCC<sup>(11)</sup> with 20 iterations, 500 bootstrap replicates, and filtering non-significant correlations (p < 0.05, two-sided). The filtered correlations were then imported into Cytoscape v3.0.2<sup>(12)</sup> to visualize them as a co-occurrence network. The network layout was selected as edge-weighted Spring embedded metrics in Cytoscape. We then identified groups of highly connected bacteria within this network. This problem is equivalent to the problem of finding maximal cliques in a graph: a clique is defined as any subset of vertices (i.e. bacteria) such that they are all adjacent, and a maximal clique is a clique that cannot be further extended. Finding all maximal cliques in a graph can be efficiently performed using the Bron-Kerbosch algorithm<sup>(13)</sup>. Because bacteria within a maximal clique are, by definition, adjacent to each other, they must also be significantly correlated to each other and thus their correlation with biomarkers is of similar magnitude.

#### <u>Assays</u>

Determinations of plasma concentrations of glucose by the glucose oxidase method (Analox Instruments, Lunenburg MA), insulin by radioimmunoassay (RIA) (Millipore, St. Charles MO, serum amyloid A (SAA) protein by Elisa (Frederick MD), high-sensitivity C-reactive protein (hs-CRP) by Roche Integra 400 plus (Roche, Indianapolis IN), bile acids by liquid chromatography-mass spectrometry, TMAO, betaine and choline by liquid chromatography/ mass spectrometry in both positive and negative mode, SCFA by electron ionization for gas chromatography-mass spectrometry without derivatization, lipid panel, liver function tests and white cell counts were done by the Columbia University Diabetes Research Center Translational Bioanalytical Core, the Columbia University Irving biomarker core, and the Michigan Metabolomic Core, all certified Core

Laboratories. The homeostatic model for assessment of insulin resistance (HOMA-IR) was calculated<sup>(14)</sup>.

## References

[1] Caporaso JG, Lauber CL, Walters WA, et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. The ISME Journal. 2012;6:1621-4.

[2] Clemente JC, Pehrsson EC, Blaser MJ, et al. The microbiome of uncontacted Amerindians. Science Advances. 2015;1:e1500183.

[3] Edgar RC. Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 2010;26:2460-1.

[4] McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. The Isme Journal. 2011;6:610-18.

[5] Faith DP. Conservation evaluation and phylogenetic diversity. Biological Conservation. 1992;61:1-10.

[6] Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Applied and environmental microbiology. 2005;71:8228-35.

[7] Knights D, Parfrey LW, Zaneveld J, Lozupone C, Knight R. Human-associated microbial signatures: examining their predictive value. Cell host & microbe. 2011;10:292-6.

[8] Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biology. 2011;12:R60.

[9] Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature biotechnology. 2013;31:814-21.

[10] Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. Bioinformatics. 2014;30:3123-4.

[11] Friedman J, Alm EJ. Inferring Correlation Networks from Genomic Survey Data. PLoS Computational Biology. 2012;8:e1002687.

[12] Shannon P, Markiel A, Ozier O, et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research. 2003;13:2498-504.

[13] Bron C, Kerbosch J. Finding All Cliques of an Undirected Graph. Commun Acm. 1973;16:575-7.

[14] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.

	BCN	NYC	Р
N	12	14	
Age (years)	44.5 (12.2)	39.5 (11.2)	0.258
Gender (% women)	83.3	85.7	
Weight (kg)	118.0 (18.6)	127.4 (14.8)	0.237
BMI (kg/m <sup>2</sup> )	45.6 (8.5)	46.5 (3.9)	0.181
Systolic Blood Pressure (mmHg)	128.6 (12.3)	122.4 (12.1)	0.189
Diastolic Blood Pressure (mmHg)	71.4 (17.9)	72.1 (18.6)	0.553
Fasting Glucose (mmol/L)	6.7 (3.6)	6.5 (1.8)	0.237
Fasting Insulin (pmol/L)	190.3 (108.3)	193.1 (76.4)	0.877
HOMA-IR	8.0 (6.0)	8.1 (3.8)	0.328
HbA1c (%)	6.4 (1.2)	6.0 (0.6)	0.486
T-CHOL (mmol/L)	4.8 (1.1)	4.9 (1.1)	0.719
HDL (mmol/L)	1.2 (0.3)	1.3 (0.4)	0.341
LDL (mmol/L)	3.0 (1.0)	2.8 (0.8)	0.703
Triglycerides (mmol/L)	1.7 (1.0)	1.6 (1.2)	0.554
WBC (K/mcL)	8.5 (2.5)	7.8 (2.1)	0.681
SAA (ng/mL)	67.7 (66.9)	50.8 (35.4)	0.797
hs-CRP (mg/L)	7.3 (4.6)	11.4 (9.0)	0.217

# <u>Supplemental Table 1</u>: Comparison of Barcelona (BCN) and the New York City (NYC) cohorts at pre-surgery

Data are presented as mean (SD). SAA: serum amyloid A; hsCRP: ultrasensitive C reactive protein. WBC: white cell count.

	BCN	NYC	Р
Ν	12	14	
Δ Weight (kg)	41.7 (12.9)	41.4 (10.4)	0.944
Δ Weight (%)	35.0 (7.5)	32.3 (6.0)	0.324
$\Delta$ BMI (kg/m <sup>2</sup> )	16.0 (4.6)	15.3 (3.8)	0.627
Δ SBP (mmHg)	1.9 (21.6)	5.3 (10.1)	0.615
Δ DBP (mmHg)	4.3 (18.7)	4.3 (17.8)	0.252
<b>Δ</b> Fasting Glucose (mmol/L)	2.3 (3.7)	1.5 (1.9)	0.483
Δ Fasting Insulin (pmol/L)	101.4 (90.3)	130.6 (66.7)	0.356
Δ HOMA-IR	5.4 (5.2)	6.2 (3.2)	0.629
Δ HbA1c (%)	1.1 (1.2)	0.6 (0.5)	0.272
Δ T-CHOL (mmol/L)	0.1 (1.3)	0.6 (1.0)	0.362
Δ HDL-C (mmol/L)	0.4 (0.3)	0.2 (0.4)	0.311
Δ LDL-C (mmol/L)	0.2 (1.3)	0.4 (0.8)	0.668
$\Delta$ Triglycerides (mmol/L)	0.8 (0.9)	0.3 (0.6)	0.186
Δ WBC (K/mcL)	2.0 (1.1)	1.1 (2.2)	0.283
Δ SAA (ng/mL)	48.0 (60.0)	34.0 (30.1)	0.463
$\Delta$ hs-CRP (mg/L)	5.9 (3.7)	10.4 (8.9)	0.122

Supplemental Table 2: Comparison of the effect of surgical weight loss between the NYC and BCN cohorts.

Delta ( $\Delta$ ) change of weight, systolic (SBP) and diastolic (DBP) blood pressure and circulating biomarkers of metabolism and inflammation. Data are presented as mean (SD). WBC: white blood count; SAA: serum amyloid A; hsCRP: ultrasensitive C reactive

	SG		RYGB		
	Pre- surgery	12 months	Pre- surgery	12 months	Р
N	7	7	5	5	
Age (years)	50.2 (9.4)	N/A	36.6 (11.9)	N/A	0.069
Weight (kg)	113.7 (20.4)	76.3 (16.4) <sup>***</sup>	123.8 (15.8)	76.3 (5.8)**	0.787
Weight loss (kg)	N/A	37.5 (10.4)	N/A	47.6 (14.9)	0.234
Weight loss (%)	N/A	33.0 (6.9)	N/A	37.7 (8.1)	0.326
Excess weight loss (%)		78.34 (22.88)		75.33 (15.91)	0.707
BMI (kg/m <sup>2</sup> )	46.4 (10.3)	31.0 (7.4) ***	44.4 (5.8)	27.6 (4.2)***	0.538
SBP (mmHg)	127.3 (14.5)	131.0 (20.2)	130.4 (9.6)	120.6 (9.2)	0.575
DBP (mmHg)	75.4 (13.9)	79.0 (9.1)	65.8 (23.0)	71.0 (9.2)	0.442
Fasting Glucose (mmol/L)	7.0 (4.5)	4.3 (0.5)*	6.4 (2.2)	4.6 (0.3)	0.406
Fasting Insulin (µU/mL)	25.0 (15.5)	12.6 (7.2)*	30.6 (17.0)	12.9 (5.9)*	0.214
HOMA-IR	6.6 (4.7)	$2.5(1.7)^{*}$	9.9 (7.7)	2.7 (1.4)	0.048
HbA1c (%)	6.5 (1.4)	5.4 (0.3)*	6.3 (1.1)	5.3 (0.2)	0.936
T-CHOL (mmol/L)	5.1 (1.0)	5.6 (0.9)	4.4 (1.3)	3.5 (1.1)	0.379
HDL-C (mmol/L)	1.1 (0.3)	1.6 (0.3) **	1.2 (0.2)	1.5 (0.3)	0.242
LDL-C (mmol/L)	3.3 (1.0)	3.5 (0.7)	2.5 (1.0)	1.7 (0.9)	0.610
Triglycerides (mmol/L)	2.0 (1.1)	$1.1 (0.6)^*$	1.4 (0.9)	0.65 (0.2)	0.808
WBC (K/mcL)	9.2 (2.8)	6.3 (1.1)*	7.35 (1.5)	5.6 (1.3)**	0.262
SAA (ng/mL)	83.8 (80.1)	19.6(13.2)*	45.1 (37.6)	19.9 (24.0)	0.338
hs-CRP (mg/L)	9.1 (4.6)	1.9 (1.3)**	4.8 (3.7)	$0.6(0.6)^{*}$	0.812

<u>Supplemental Table 3</u>: Comparison of the two surgery groups (SG n=7 and RYGB n=5) in the BCN cohort.

Differences from pre- and post-surgery within in surgical group: \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001. Data are presented as mean (SD). Analyses performed via Wilcoxon signed-rank test or paired t-test. SBP: systolic blood pressure; DBP: diastolic blood pressure; SAA: serum amyloid A; hsCRP: ultrasensitive C reactive protein; RYGB: Roux-en-Y gastric bypass; SG: sleeve gastrectomy. P values are for differences between surgical groups of delta change from pre-surgery to 12 months. Analyses performed via Wilcoxon rank-sum test or independent sample t-test.

# Supplemental Table 4: Spearman Correlations between individual circulating bile acids and stool bacteria

Months: month since surgery; Taxa: p=phylum, c=class, o=order, f=family, g=genus

Bile acids	Corr coef	P value	Таха	Fdr	Bonferroni	Months
Conj12AlphaOH	-1	0	p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales; f Enterobacteriaceae	0	0	3
Conj12AlphaOH	-1	0	 pProteobacteria;cGammaproteobacteria;oEnterobacteriales	0	0	3
CA	0 991071429	1 44F-05	p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales; f_Enterobacteriaceae;g_Pantoea	0 005773946	0 005773946	r
Conj12AlphaOH	-0.964285714	0.000454149	p Proteobacteria	0.045528454	0.182113817	3
Conj12AlphaOH	-0.964285714	0.000454149	pProteobacteria;cGammaproteobacteria	0.045528454	0.182113817	3
CA.	0 964285714	0 000454149	p_Proteobacteria;c_Gammaproteobacteria;o_Enterobacteriales;	0.045528454	0 192112917	2
CA	0.504285714	0.000434143	p_Firmicutes;c_Clostridia;o_Clostridiales;f_Lachnospiraceae;	0.043328434	0.102113017	5
СА	-0.964285714	0.000454149	g_[Ruminococcus]	0.045528454	0.182113817	3
СА	0.964285714	0.000454149	f_Enterobacteriaceae;g_Erwinia	0.045528454	0.182113817	3
GCDCA	0.964285714	0.000454149	pProteobacteria;cGammaproteobacteria;oPasteurellales	0.060704606	0.182113817	3
GCDCA	0.964285714	0.000454149	pProteobacteria;cGammaproteobacteria;oPasteurellales; fPasteurellaceae	0.060704606	0.182113817	3
GCDCA	0 964285714	0 000/15/11/9	p_Proteobacteria;c_Gammaproteobacteria;o_Pasteurellales;	0.060704606	0 182113817	3
GEDEA	0.504205714	0.000454145	p_Proteobacteria;cGammaproteobacteria;oEnterobacteriales;	0.000704000	0.102113017	5
CA	0.955357143	0.000789528	fEnterobacteriaceae;gCitrobacter	0.063320125	0.316600624	3
Secondary	-0.964285714	0.000454149	pProteobacteria	0.091056908	0.182113817	3
Secondary	-0.964285714	0.000454149	pProteobacteria;cGammaproteobacteria	0.091056908	0.182113817	3
Secondary UnC	-0.928571429	0.002519472	p_Firmicutes;c_Clostridia;o_Clostridiales;f_Christensenellaceae	0.144329776	1	3
Secondary UnC	-0.928571429	0.002519472	prirmicutes;cClostridia;oClostridiales;rChristensenellaceae;   g	0.144329776	1	3
Secondary UnC	0.964285714	0.000454149	p_Firmicutes;c_Bacilli;o_Lactobacillales;f_Leuconostocaceae; g_Weissella	0.144329776	0.182113817	3
Secondary UnC	0.928571429	0.002519472	p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales; f_Alcaligenaceae:g_Sutterella	0.144329776	1	3
,			p_Proteobacteria;c_Betaproteobacteria;o_Burkholderiales;			
Secondary UnC	0.928571429	0.002519472	f_Alcaligenaceae p Bacteroidetes;c Bacteroidia;o Bacteroidales;f Prevotellacea	0.144329776	1	3
Secondary UnC	0.928571429	0.002519472	e; gPrevotella	0.144329776	1	3
Secondary UnC	0.928571429	0.002519472	p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Prevotellacea e	0.144329776	1	3
TDCA	0.064285714	0.000454140	p_Bacteroidetes;c_Bacteroidia;o_Bacteroidales;f_Porphyromon	0 100110017	0 102112017	2
IDCA	0.964285714	0.000454149	pProteobacteria;cDeltaproteobacteria;oDesulfovibrionales;	0.182113817	0.182113817	3
Total UC	0.964285714	0.000454149	f_Desulfovibrionaceae;g_Bilophila	0.182113817	0.182113817	3
Total C	-0.964285714	0.000454149	prmitcutes;cclostridia;bclostridiales;itacrinospiraceae; gRoseburia	0.182113817	0.182113817	3
ΤΟCΑ	-0.964285714	0 000/15/11/9	pFirmicutes;cClostridia;oClostridiales;fLachnospiraceae; 	0 182113817	0 182113817	3
	0.504205714	0.000454145	pFirmicutes;cClostridia;oClostridiales;fRuminococcaceae;	0.102113017	0.102113017	5
CDCA	0.964285714	0.000454149	gFaecalibacterium	0.091056908	0.182113817	6
CDCA	0.964285714	0.000454149	p_Actinobacteria	0.091056908	0.182113817	6
GCDCA	0.964285714	0.000454149	g_Acidaminococcus	0.182113817	0.182113817	6
Secondary	-0.964285714	0.000454149	pFirmicutes;cClostridia;oClostridiales;fRuminococcaceae; gRuminococcus	0.182113817	0.182113817	6
			p_fructures;c_Clostridia;o_Clostridiales;f_Clostridiaceae;			
Conjugated	-1	0	gClostridium pFirmicutes;cClostridia;oClostridiales;fClostridiaceae;	0	0	12
12-Alpha-OH	-1	0	g_Clostridium	0	0	12
Primary UC	1	0	p_Firmicutes;c_Clostridia;o_Clostridiales;f_Ruminococcaceae	0	0	12
Non12AlphaOH	-0.973214286	0.000222306	prroteobacteria;cGammaproteobacteria;oAeromonadales; fAeromonadaceae;g	0.044572372	0.089144743	12
ТСА	-0.973214286	0.000222306	p_Proteobacteria;cGammaproteobacteria;oAeromonadales; f Aeromonadaceae;g	0.044572372	0.089144743	12

Bile acids	Corr coef	P value	Таха	Fdr	Bonferroni	Months
			pProteobacteria;cGammaproteobacteria;oAeromonadales;			
Non12AlphaOH	-0.973214286	0.000222306	fAeromonadaceae	0.044572372	0.089144743	12
			pProteobacteria;cGammaproteobacteria;oAeromonadales;			
TCA	-0.973214286	0.000222306	fAeromonadaceae	0.044572372	0.089144743	12
			p_Proteobacteria;cGammaproteobacteria;oEnterobacteriale			
TCA	-0.964285714	0.000454149	s; fEnterobacteriaceae;gKlebsiella	0.045528454	0.182113817	12
			pProteobacteria;cGammaproteobacteria;oEnterobacteriale			
TCA	-0.964285714	0.000454149	s; fEnterobacteriaceae;gErwinia	0.045528454	0.182113817	12
CA	0.964285714	0.000454149	pFirmicutes;cClostridia;oClostridiales;fRuminococcaceae	0.182113817	0.182113817	12
Total UC	0.964285714	0.000454149	pFirmicutes;cClostridia;oClostridiales;fRuminococcaceae	0.182113817	0.182113817	12
CDCA	0.964285714	0.000454149	pFirmicutes;cClostridia;oClostridiales;fRuminococcaceae	0.182113817	0.182113817	12
			pFirmicutes;cClostridia;oClostridiales;fClostridiaceae;			
SecondConj	-0.964285714	0.000454149	gClostridium	0.182113817	0.182113817	12
			pFirmicutes;cClostridia;oClostridiales;fVeillonellaceae;			
GDCA	-0.964285714	0.000454149	gDialister	0.182113817	0.182113817	12
GCDCA	-0.964285714	0.000454149	pActinobacteria;cActinobacteria;oActinomycetales	0.182113817	0.182113817	12
			pFirmicutes;cClostridia;oClostridiales;fClostridiaceae;			
All Conj	-0.964285714	0.000454149	gClostridium	0.182113817	0.182113817	12
			pFirmicutes;cClostridia;oClostridiales;fClostridiaceae;			
All BA	-0.964285714	0.000454149	gClostridium	0.182113817	0.182113817	12
			pFirmicutes;cClostridia;oClostridiales;fClostridiaceae;			
GDCA	-0.964285714	0.000454149	gClostridium	0.182113817	0.182113817	12

# Supplemental Table 5: Bile acids definitions

		Hydroxyl group removed from CA by gut bacteria then
DCA	deoxycholic	becomes DC
CDCA	chenodeoxycholic	
UDCA	ursodeoxycholic	Epimer of CDC
CA	cholic acid	
		Hydroxyl group removed from CDC by gut bacteria then
LCA	lithocholic	becomes LC

## **Unconjugated Bile Acids (Primary is red, Secondary is Blue)**

### Glycine Conjugated Bile Acids (aka Bile Salts) (Primary is green, Secondary is violet)

GDCA	glyco-deoxycholic	
	glyco-	
GCDCA	chenodeoxycholic	
GUDCA	glyco-ursodeoxycholic	
GCA	glyco-cholic acid	
GLCA	glyco-lithocholic	

## Taurine Conjugated Bile Acids (aka Bile Salts) (Primary is green, Secondary is violet)

TDCA	tauro-deoxycholic	
	tauro-	
TCDCA	chenodeoxycholic	
TUDCA	tauro-ursodeoxycholic	
TCA	tauro-cholic acid	
TLCA	tauro-lithocholic	

Key

Primary Bile Acids	Primary bile acids (CDC and CA)
Primary Bile Salts	Primary bile salts (GCDC, TCDC, GCA, TCA)
Secondary Bile Acids	Secondary bile acids (DC, UDC, LC)
Secondary Bile Salts	Secondary bile salts (GDC, TDC, GUDC, TUDC, GLC, TLC)

**Supplemental Figure 1**: Magnitude of change (express as percent increase and percent decrease) of clinical characteristics and metabolic biomarkers (A) and circulating biomarkers of inflammation and microbial metabolism (B), for the entire cohort (n=26), one year after surgery. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001.



## Supplemental Figure 2: Pathway Analysis

Relative abundance of all microbial metabolism pathways significantly (false discovery rate (FDR) p < 0.05) enriched between pre-surgery and 3m (A), pre-surgery and 6m (B), and pre-surgery and 12m (C). Effect size of differences between pre- and post-surgery, estimated as  $\eta^2$ . Change overtime of the relative abundance of pathways differentially enriched pre- and post-surgery (D).



Supplemental Figure 3: Correlations Analyses

Partial correlations between bacterial taxa and biomarkers significant after false discovery rate (FDR) correction.

Bacteroides with heptanoate (A); Bifidobacterium with total cholesterol (B), LDL cholesterol (C) and weight loss (D); Bautia with butyrate (E) and choline (F); Butyricimonas with isobutyrate (G), and HDL (H).



Supplemental Figure 4: Network Analyses

Network analysis of co-occurring bacteria at pre-surgery (A), 3m (B), 6m (C), 12m (D) post-surgery.

Circles represent bacterial taxa at the genus level, with color indicating relative abundance from red (high) to yellow (low). Edges between nodes indicate significant correlations (blue: positive; dashed gray: negative), with length of the edge representing strength of the correlation (shorter edges indicating higher correlation). Triangles represent biomarkers that are significantly correlated with bacterial clusters, magnified in the sub-panels.



